Uncategorized
ONL Therapeutics awarded NEI grant to develop treatment for retinal disease
The National Eye Institute awarded ONL Therapeutics a $1.37 million grant to develop ONL101, a first-in-class small molecule peptide designed to protect photoreceptors in retinal detachment, according to a press release.ONL101 was previously given orphan drug designation for retinal detachment.